The Clinical Management of Recurrent Genital Herpes: Current Issues and Future Prospects

Herpes

Volumn 9, Issue 1, 2002, Pages 15-20

  Barton, Simon E ^a   Ebel, Charles W ^b   Kirchner, Jeffrey T ^c   Mertz, Gregory J ^d  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b American Social Health Association   (United States)

^c LANCASTER GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral therapy; Clinical management; Herpes simplex virus (HSV); Immune response modifiers; Immunotherapy; Nucleoside analogues; Panel discussion; Recurrent genital herpes; Resiquimod

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; FAMCICLOVIR; HERBACEOUS AGENT; HERPES SIMPLEX VACCINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 12; NATURAL PRODUCT; NUCLEOSIDE ANALOG; RESIQUIMOD; TUMOR NECROSIS FACTOR ALPHA; VALACICLOVIR; IMMUNOLOGICAL ADJUVANT;

CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSULTATION; COST OF ILLNESS; CYTOKINE PRODUCTION; DOCTOR PATIENT RELATION; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; GENITAL HERPES; HEALTH CARE AVAILABILITY; HEALTH PROMOTION; HERPES SIMPLEX VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION RISK; MEDICAL SPECIALIST; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT REFERRAL; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT INFECTION; REVIEW; SELF MEDICATION; SEXUAL TRANSMISSION; SIDE EFFECT; SYMPTOM; UNITED KINGDOM; UNITED STATES; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TRANSMISSION; ARTICLE; RECURRENT DISEASE;

SIMPLEXVIRUS;

ADJUVANTS, IMMUNOLOGIC; ANTIVIRAL AGENTS; GREAT BRITAIN; HERPES GENITALIS; PATIENT CARE; PATIENT EDUCATION; PHYSICIAN-PATIENT RELATIONS; RECURRENCE; SELF MEDICATION; UNITED STATES;

EID: 0036550344     PISSN: 09697667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Robinson NJ, Hosseini M. Age-specific herpes simplex virus type 2 seroprevalence in general populations: estimates from around the globe (poster). Proceedings of the Joint Meeting of the Medical Society for the Study of Venereal Diseases and American Sexually Transmitted Diseases Association, Baltimore, USA, 2000.
2. Lafferty WE, Downey L, Celum C, Wald A. Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J Infect Dis 2000;181:1454-1457.
3. Johnson RE, Nahmias AJ, Magder LS, Lee FK, Brooks CA, Snowden CB. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med 1989;321:7-12.
4. Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-1111.
5. Corey L, Handsfield HH. Genital herpes and public health. JAMA 2000;283:791-794.
6. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998;26:541-553.
7. Hook EW, Cannon RO, Nahmias AJ, Lee FF, Campbell CH, Jr, Glasser D et al. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J Infect Dis 1992;165:251-255.
8. Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998;101:1500-1508.
9. Spruance SL. Gender-specific efficacy of a prophylactic SBAS-4-adjuvanted gD2 subunit vaccine against genital herpes disease (GHD): results of two clinical efficacy trials. The Herpes Vaccine Efficacy Group (abstract). Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000.
10. Spruance SL, Tyring SK, Smith MH, Meng TC. Application of a topically-applied immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis 2001;184:196-200.
11. Hessol NA, Priddy FH, Bolan G, Baumrind N, Vittinghoff E, Reingold AL et al. Management of pelvic inflammatory disease by primary care physicians. Sex Transm Dis 1996;23:157-163.
12. Davis K. Universal coverage in the United States: lessons from experience of the 20th century. J Urban Health 2001;78:46-58.
13. IHMF. The Medical Importance of Genital Herpes Simplex Virus Infection. Recommendations of the International Management Strategies Forum management strategies workshop, 1997. Available at: www.ihmf.org/ library/lib_mon.asp
14. Vonau B, Barton SE, Gazzard BG. Sharing prescribing of continuous aciclovir treatment: effect of a new policy and general practitioner responses. Genitourin Med 1997;73:225-226.
15. Romanovsky B, Grant ZA, Taback N. An open design study to determine subject treatment preference of once daily valacyclovir as suppressive therapy versus valacyclovir twice daily episodic treatment for recurrent genital herpes infections (abstract). Proceedings of 40th Interscience Conference on Antimicrobiol Agents and Chemotherapy, Toronto, Canada, 2000.
16. Carney O, Ross E, Bunker C, Ikkos G, Mindel A. A prospective study of the psychological impact on patients with a first episode of genital herpes. Genitourin Med 1994;70:40-45.
17. Patel R, Boselli F, Cairo I, Barnett G, Price M, Wulf HC. Patients' perspectives on the burden of recurrent genital herpes. In J STD AIDS 2001;12:640-645.
18. Clinical Effectiveness Group (Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). 2001 National Guideline for the Management of Genital Herpes. Available at: www.mssvd.org.uk/ceg.htm
19. Centers for Disease Control and Prevention. Guidelines for treatment of sexually transmitted diseases. MMWR Morb Mortal Wkly Rep 1998;47 (RR-1):1-111.
20. Patel R, Tyring S, Strand A, Price MJ, Grant DM. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect 1999;75:398-402.
21. Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS. Recurrence and resistance patterns of herpes simplex virus following cessation of >6 years of chronic suppression with acyclovir. J Infect Dis 1994;169:1338-1341.
22. Mertz GJ, Management of genital herpes. In: Antiviral Chemotherapy 4 (Mills J, Volberding P, Corey L). New York: Plenum Press, 1996;pp1-10.
23. Barton SE. Herpes management and prophylaxis. Sex Transm Dis 1998;16:799-803.
24. Barton SE, Munday PE, Patel RJ. Asymptomatic shedding of herpes simplex virus from the genital tract: uncertainty and its consequences for patient management. Int J STD AIDS 1996;7:229-232.
25. Patel R, Cowan FM, Barton SE. Advising patients with genital herpes. BMJ 1997;314:85-86.
26. Russell JM, Barton SE, Lawrence AG. Self-medication by women attending a genitourinary medicine clinic. Int J STD AIDS 1990;1:279-281.
27. Vonau B, Chard S, Mandalia S, Wilkinson D, Barton SE. Does the extract of the plant Echinacea purpurea influence the clinical course of recurrent genital herpes? Int J STD AIDS 2001;12:154-158.
28. Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med 1999;131:14-20.
29. Mindel A. Psychological and psychosexual implications of herpes simplex virus infections. Scand J Infect Dis 1996 (Suppl);100:27-32.
30. Rooney JF, Straus SE, Mannix ML, Wohlenberg CR, Banks S, Jagannath S, et al. UV light-induced reactivation of herpes simplex virus type 2 and prevention by acyclovir. J Infect Dis 1992;166:500-506.
31. Cassidy L, Meadows J, Catalan J, Barton S. Are reported stress and coping style associated with frequent recurrence of genital herpes? Genitourin Med 1997;73:263-266.
32. Cohen F, Kemeny ME, Kearney KA, Zegan LS, Neuhaus JM, Conant MA. Persistent stress as a predictor of genital herpes recurrence. Arch Intern Med 1999;159:2430-2436.
33. Rein M. Stress and genital herpes recurrences in women. JAMA 2000;283:1394.
34. Russell JM, Cracknell M, Barton SE, Catalan J. Management of genital herpes by genitourinary physicians: does experience or doctor's gender influence clinical management? Genitourin Med 1993;69:115-118.
35. American Social Health Association. New Survey Reveals Americans Underestimate their Risk of Contracting Genital Herpes, April 2000. Available at: www.ashastd.org/ news/042600.html
36. Breinig MK, Kingsley LA, Armstrong JA, Freeman DJ, Ho M. Epidemiology of genital herpes in Pittsburgh: serologic, sexual, and racial correlates of apparent and inapparent herpes simplex infections. J Infect Dis 1990;162:299-305.
37. Frenkel LM, Garratty EM, Shen JP, Wheeler N, Clark O, Bryson YJ. Clinical reactivation of herpes simplex virus type 2 infection in seropositive pregnant women with no history of genital herpes. Ann Intern Med 1993;118:414-418.
38. Langenberg A, Benedetti J, Jenkins J, Ashley R, Winter C, Corey L. Development of clinically recognizable genital lesions among women previously identified as having 'asymptomatic' herpes simplex virus type 2 infection. Ann Intern Med 1989;110:882-887.
39. Siegel D, Golden E, Washington AE, Morse SA, Fullilove MT, Catania JA et al. Prevalence and correlates of herpes simplex infections. The population-based AIDS in multiethnic neighborhoods Study. JAMA 1992:268:1702-1708.
40. Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R et al. Reactivation of genital herpes virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000;342:844-850.
41. Wald A, Langenberg AG, Link K, Izu AE, Ashley R, Warren T et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001;285:3100-3106.
42. Leung DT, Sacks SL. Current recommendations for the treatment of genital herpes. Drugs 2000;60:1329-1352.
43. Miller RL, Tomai MA, Harrison CJ, Bernstein DI. Immunomodulation as a treatment strategy for genital herpes: review of the evidence. Int Immunopharmacol 2002 (in press).
44. Bernstein DI, Harrison CJ. Imiquimod in the guinea pig model of genital herpes: an antiviral and adjuvant. In: Cutaneous Infection and Therapy (Aly R, Beutner KR, Maibach H, eds). New York: Marcel Dekker, 1997; pp417-428.
45. Conant MA, Berger TG, Coates TJ, Lingo DJ, Robinson JK, Drake LA. Genital herpes: an integrated approach to management. J Am Acad Dermatol 1996;35:601-605.